

AMENDMENTS

IN THE CLAIMS

Please amend the claims as shown below. The amendments shown below are in addition to the amendments entered by the Examiner, as set forth in the Examiner's Amendment provided with the Notice of Allowability mailed January 13, 2010.

1-26. (Canceled)

27. (Previously Presented) A polynucleotide adjuvant composition comprising:
a polyribonucleosinic-polyribocytidylic acid (PIC),
an antibiotic, and
a positive ion,

wherein the composition is suitable for use in humans and contains polynucleotide adjuvant composition molecules heterogeneous for at least one of molecular weight or size, wherein the molecular weight is in a molecular weight range of from 338,000 to 1,200,000 Daltons and wherein the size is in a molecular size range of from 13.5 to 24.0 Svedbergs.

28-30. (Canceled)

31. (Previously Presented) A polynucleotide adjuvant composition comprising:
a polyribonucleosinic-polyribocytidylic acid (PIC),
an antibiotic, and
a positive ion,

wherein the composition is suitable for use in humans and contains polynucleotide adjuvant composition molecules that have an average molecular weight greater than 338,000 Daltons or have an average molecular size greater than 13.5 Svedbergs.

32. (Previously Presented) The polynucleotide adjuvant composition of claim 31, wherein the average molecular weight is equal to or greater than 500,000 Daltons or the average molecular size is equal to or greater than 15 Svedbergs.

33. (Canceled)

34. (Previously Presented) The polynucleotide adjuvant composition of any of claims 27, 31 or 32, wherein the antibiotic is kanamycin, neomycin, an anthracycline, butirosin sulfate, a gentamicin, hygromycin, amikacin, dibekacin, nebramycin, metrzamide, puromycin, streptomycin, or streptozocin.

35. (Previously Presented) The polynucleotide adjuvant composition of any of claims 27, 31 or 32, wherein the antibiotic is kanamycin, neomycin, an anthracycline, butirosin sulfate, a gentamicin, hygromycin, amikacin, dibekacin, nebramycin, metrzamide, puromycin, streptomycin, or streptozocin and the positive ion is calcium, cadmium, lithium, magnesium, cerium, cesium, chromium, cobalt, deuterium, gallium, iodine, iron, or zinc; and wherein the positive ion is the form of an inorganic salt or an organic complex.

36. (Previously Presented) The polynucleotide adjuvant composition of any of claims 27, 31 or 32, wherein the antibiotic is kanamycin, neomycin, an anthracycline, butirosin sulfate, a gentamicin, hygromycin, amikacin, dibekacin, nebramycin, metrzamide, puromycin, streptomycin, or streptozocin and the source of positive ions is calcium chloride, calcium carbonate, calcium fluoride, calcium hydroxide, calcium phosphates, or calcium sulfate.

37. (Previously Presented) The polynucleotide adjuvant composition of any of claims 27, 31 or 32, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

38. (Previously Presented) A kit comprising the polynucleotide adjuvant composition of any of claims 27, 31 or 32 and an antigenic compound, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

39-45. (Canceled)

46. (Previously Presented) A method for enhancing an immune response to an antigenic compound, comprising: administering to a subject a composition comprising an antigenic compound and the polynucleotide adjuvant composition of any of claims 27, 31 or 32, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

47. (Previously Presented) The method of claim 46, wherein said administering is by parenteral injection, intramuscular injection, intraperitoneal injection, intravenous injection, subcutaneous injection, inhalation, rectal delivery, vaginal delivery, nasal delivery, oral delivery, ophthalmic delivery, topical delivery, transdermal delivery or intradermal delivery.

48-51. (Canceled)

52. (Previously Presented) The polynucleotide adjuvant composition of claim 34, wherein the antibiotic is kanamycin.

53. (Previously Presented) The polynucleotide adjuvant composition of any of claims 27, 31 or 32, wherein the positive ion is calcium, cadmium, lithium, magnesium, cerium, cesium, chromium, cobalt, deuterium, gallium, iodine, iron, or zinc.

54. (Previously Presented) The polynucleotide adjuvant composition of claim 53, wherein the positive ion is calcium.

55. (Previously Presented) An immunogenic composition, comprising:
a polynucleotide adjuvant composition comprising a polyribonucleosinic-
polyribocytidylic acid (PIC), an antibiotic, and a positive ion; and
an antigenic compound;
wherein the composition is suitable for use in humans and contains polynucleotide
adjuvant composition molecules that have an average molecular weight greater than 338,000
Daltons or have an average molecular size greater than 13.5 Svedbergs.
56. (Previously Presented) The immunogenic composition of claim 55, wherein the
antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.
57. (Previously Presented) The immunogenic composition of claim 55, wherein the
antigenic compound is a human antigen, a non-human animal antigen, a plant antigen, bacterial
antigen, a fungal antigen, a viral antigen, a parasite antigen, or a cancer antigen.
58. (Previously Presented) The immunogenic composition of claim 57, wherein the
viral antigen is a rabies antigen.
59. (Previously Presented) The immunogenic composition of claim 58, wherein the
rabies antigen is an inactivated purified rabies antigen.
60. (**Currently Amended**) The immunogenic composition of claim 55, wherein
polynucleotide adjuvant composition is capable of eliciting an enhanced **combined** specific
humoral and/or cell mediated immune response.
61. (Previously Presented) The immunogenic composition of claim 55, wherein at
least one of the adjuvant composition or the immunogenic composition is in a solid form or a
liquid form, wherein the liquid form is a solution or a suspension.
62. (Previously Presented) The immunogenic composition of claim 55, wherein at
least one of the adjuvant composition or the immunogenic composition is freeze-dried.

63. (Previously Presented) An immunogenic composition, comprising:
a polynucleotide adjuvant composition comprising a polyriboinosinic-polyribocytidylic acid (PIC), an antibiotic, and a positive ion, wherein the antibiotic is kanamycin and the positive ion is calcium; and
an antigenic compound;
wherein the composition is suitable for use in humans and contains polynucleotide adjuvant composition molecules that have an average molecular weight greater than 338,000 Daltons or have an average molecular size greater than 13.5 Svedbergs.

64. (Canceled)

65. (Previously Presented) The immunogenic composition of claim 63, wherein the antigenic compound is a human antigen, a non-human animal antigen, a plant antigen, bacterial antigen, a fungal antigen, a viral antigen, a parasite antigen, or a cancer antigen.

66. (Previously Presented) The immunogenic composition of claim 65, wherein the viral antigen is a rabies antigen.

67. (Previously Presented) The immunogenic composition of claim 66, wherein the rabies antigen is an inactivated purified rabies antigen.

68. (**Currently Amended**) The immunogenic composition of claim 63, wherein polynucleotide adjuvant composition is capable of eliciting an enhanced ~~combined~~ specific humoral and/or cell mediated immune response.

69. (Previously Presented) The immunogenic composition of claim 63, wherein at least one of the adjuvant composition or the immunogenic composition is in a solid form or a liquid form, wherein the liquid form is a solution or a suspension.

70. (Previously Presented) The immunogenic composition of claim 63, wherein at least one of the adjuvant composition or the immunogenic composition is freeze-dried.

71. (Previously Presented) An immunogenic composition, comprising:
a polynucleotide adjuvant composition comprising a polyriboinosinic-polyribocytidylic acid (PIC), an antibiotic, and a positive ion; and
an antigenic compound;
wherein the composition is suitable for use in humans and contains polynucleotide adjuvant composition molecules heterogeneous for at least one of molecular weight or size, wherein the molecular weight is in a molecular weight range of from 338,000 to 1,200,000 Daltons and wherein the size is in a molecular size range of from 13.5 to 24.0 Svedberg.

72. (Previously Presented) The immunogenic composition of claim 71, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

73. (Previously Presented) The immunogenic composition of claim 71, wherein the antigenic compound is a human antigen, a non-human animal antigen, a plant antigen, bacterial antigen, a fungal antigen, a viral antigen, a parasite antigen, or a cancer antigen.

74. (Previously Presented) The immunogenic composition of claim 73, wherein the viral antigen is a rabies antigen.

75. (Previously Presented) The immunogenic composition of claim 74, wherein the the rabies antigen is an inactivated purified rabies antigen.

76. (**Currently Amended**) The immunogenic composition of claim 71, wherein polynucleotide adjuvant composition is capable of eliciting an enhanced ~~combined~~ specific humoral and/or cell mediated immune response.

77. (Previously Presented) The immunogenic composition of claim 71, wherein at least one of the adjuvant composition or the immunogenic composition is in a solid form or a liquid form, wherein the liquid form is a solution or a suspension.

78. (Previously Presented) The immunogenic composition of claim 71, wherein at least one of the adjuvant composition or the immunogenic composition is freeze-dried.

79. **(Currently Amended)** A method for enhancing an immune response to an antigenic compound, comprising: administering to a subject the immunogenic composition of claims 55, **63** or 71, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

80. (Previously Presented) The method of claim 79, wherein said administering is by parenteral injection, intramuscular injection, intraperitoneal injection, intravenous injection, subcutaneous injection, inhalation, rectal delivery, vaginal delivery, nasal delivery, oral delivery, opthamalic delivery, topical delivery, transdermal delivery or intradermal delivery.

81-82. (Canceled)